Clinical Trials · NCT02823691

The MetNET-2 Trial

UnknownEARLY_Phase 1Lanreotide (Unclear)
Phase
EARLY_Phase 1
Recruitment status
Unknown
Sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Enrollment
20
Start date
Apr 2016
Locations
1 site, Italy
Primary endpoint
incidence of SAEs and AEs
View Lanreotide compound reference